High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade. Clin Prostate Cancer 2002;1:115 ^ 7.Abouelfadel Z, Miller GJ, Glode LM, et al. High Gleason scores and lower prostate-specific anti- gen levels in a single institution over the ...
Prostate specific antigen (PSA/KLK3) is known to be the chief executor of the fragmentation of semenogelins, dissolution of semen coagulum, thereby releasing sperm for active motility. Recent research has found that semenogelins also play significant roles in sperm fertility by affecting hyaluronidas...
Over the last 2 decades, prostate cancer (PCA) screening using the prostate specific antigen (PSA) test exposed the complexities and challenges associated with early screening for a common cancer [1]. PCA is a heterogeneous disease with a long natural history and a wide range of prognostic outc...
This helps your doctor predict how likely yourprostate cancer is to grow and spread, which helps them advise you on what treatment path to choose. Also, your doctor will likely also use your prostate specific antigen (PSA) levels, physical exam findings, imaging for tumor staging, and possibly...
Interpreting Your Phi Test Results Your Prostate Health Index test results will provide you with scores ranked as within range or out of range for the three tests that make up the phi score. These tests are: PSA: PSA (prostate specific antigen) is a protein that is produced by prostate cel...
The cohort of patients for HN and CR cancer were selected for analysis if they initially responded to hormone treatment (response was defined by prostate-specific antigen (PSA) levels decreasing by at least 50%), but subsequently relapsed (two consecutive increases in PSA of >10%) and had a...
The change in prostate-specific antigen (PSA) level over time, PSA velocity (PSAV), has been suggested as an aid to detection of prostate cancer. It is argued that a rapidly rising PSA may indicate a greater risk of diagnosis of prostate cancer even if PSA levels are low. Accordingly, ...
Prostate-Specific Antigen–Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Resaerch and Quality; October 2011. AHRQ publication 12-05160-EF-1. 9. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of ...
prostate-specific antigen.b, Sankey diagram depicting a proportion of duplication signatures observed across cancer subtypes. Duplication features, including amplification (Amp), translocation (trans) plus, localn-jump, templated insertion (ins), amplification loss of heterozygosity (LOH), gain, tandem ...
On the basis of the findings from the landscape analysis, Movember will now have an increased focus on addressing the specific research needs that have been identified, with particular investment in research efforts that reduce disease progression and lead to improved therapies for advanced prostate ...